FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB APPROVAL | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* TOOMAN CRAIG A (Last) (First) (Middle) C/O ENZON PHARMACEUTICALS, INC. 685 ROUTE 202/206 (Street) | | | | | | | Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS INC [ENZN] One of Earliest Transaction (Month/Day/Year) O1/05/2005 If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) Executive Vice President 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | | | | |
|--|---|--|---|--|--|-------------------------------|---|-----|--|---|--------------------|--|---|----------|--|---|--|--|--|--|--|
| (City) | EWATER N | tate) (| | | | | | | | | | | Form filed by More than One Reporting Person | | | | | | | | |
| Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transactic Date (Month/Day/ | | | | | | on 2A. Deemed Execution Date, | | | | 3. 4. Securi Transaction Disposed Code (Instr. and 5) | | | | d (A) or | 5. Amou Securiti Benefici Owned Followin | nt of es ally | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | | | v | Amount | (D) | | Price | Reporte Transac (Instr. 3 | ted action(s) 3 and 4) | | | (Instr. 4) | | |
| Common | Common Stock ⁽¹⁾ 01/05/2005 A 25,000 ⁽²⁾ A \$0 25,000 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | Execution Date, if any (Month/Day/Year) | | 4. Transaction Code (Instr 8) | | ion of | | 6. Date Exercisable a Expiration Date (Month/Day/Year) | | | e and 7. Title and Amount of Securities Underlying Derivative Sect (Instr. 3 and 4) | | | 8. Price of Derivative Security (Instr. 5) | 9. Numbe derivative Securitie Beneficia Owned Followin Reported Transacti (Instr. 4) | e s ally g | 10. Ownership Form: Direct (D) or Indirec (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Date Exercisab | | Expiration Date | Title | or Nu of | umber | | | | | | | |
| Common Stock (Right to Buy) ⁽³⁾ | \$13.08 | 01/05/2005 | | | A | | 125,000 | | (4) | (| 01/05/2015 | Commo Stock | n 12 | 25,000 | \$0 | 125,0 | 00 | D | | | |

Explanation of Responses:

- 1. Restricted stock granted by Enzon Pharmaceuticals, Inc. ("Enzon") pursuant to Enzon's 2001 Incentive Stock Plan and qualified under Rule 16b-3(d).
- 2. Of the 25,000 shares granted, 7,500 will vest on January 5, 2008, 7,500 will vest on January 5, 2009 and the remaining 10,000 will vest on January 5, 2010 so long as Mr. Tooman remains an employee of Enzon on the above dates.
- $3. \ Stock\ option\ granted\ by\ Enzon\ pursuant\ to\ Enzon's\ 2001\ Incentive\ Stock\ Plan\ and\ qualified\ under\ Rule\ 16b-3(d).$
- 4. Of the 125,000 options granted, 31,250 will vest on January 5, 2006, 31,250 will vest on January 5, 2007, 31,250 will vest on January 5, 2008 and the remaining 31,250 will vest on January 5, 2009 so long as Mr. Tooman remains an employee of Enzon on the above dates.

/s/ Gary A. Smith (Attorney-in-Fact) 01/07/2005

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.